Emerging experience with meningococcal serogroup B protein vaccines

References

• Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184–191.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–861.
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M, Wolter J, Hogea C, et al. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther. 2011;9:761–774.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Ochnio J, Ho M, et al. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerg Infect Dis. 2004;10:1812–1815.
   PubMed Web of Science ®Google Scholar
• Baccarini C, Ternouth A, Wieffer H, et al. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccines Immunother. 2013;9:162–171.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–B63.
   PubMed Web of Science ®Google Scholar
• Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9:285–298.
   PubMed Web of Science ®Google Scholar
• European Center for Disease Prevention and Control. Surveillance report. Surveillance of invasive bacterial diseases in Europe. 2012.
   Google Scholar
• Bröker M, Emonet S, Fazio C, et al. Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Hum Vaccines Immunother. 2015 Jun 2;11(9):2281–2286.
   Web of Science ®Google Scholar
• Agnememel A, Hong E, Giorgini D, et al. Neisseria meningitidis Serogroup X in Sub-Saharan Africa. Emerg Infect Dis. 2016;22:698–702.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:578–585.
   PubMed Web of Science ®Google Scholar
• Campbell H, Saliba V, Borrow R, et al. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveil. 2015;20(28). pii: 21188.
   Google Scholar
• Australian Government Department of Health Office of Health Protection. Meningococcal - Australian Meningococcal Surveillance Programme annual reports [Internet]; [2016 Jul 18]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-annlrpt-menganrep.htm
   Google Scholar
• Wormsbecker AE, Wong K, Jamieson FB, et al. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: vaccine program impact assessment. Vaccine. 2015;33:5678–5683.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58–S67.
   PubMed Web of Science ®Google Scholar
• The recommended use of the multicomponent meningococcal B (4CMenB) vaccine in Canada - Public Health Agency of Canada [Internet]; [ cited 2016 Apr 4]. Available from: http://www.phac-aspc.gc.ca/naci-ccni/mening-4cmenb-exec-resum-eng.php
   Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) [Internet]; [ cited 2016 Jun 27]. Available from: http://www.cdc.gov/abcs/reports-findings/surv-reports.html
   Google Scholar
• Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2:355–357.
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EAL, et al. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun. 2004;72:5955–5962.
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. Jama. 1999;281(16):1520–1527.
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195–207–210.
   PubMedGoogle Scholar
• Caron F, Du Châtelet IP, Leroy J-P, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455–463.
   PubMed Web of Science ®Google Scholar
• Oster P, Lennon D, O’Hallahan J, et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23:2191–2196.
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15: P1.3)outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. 1995;13:821–829.
   PubMed Web of Science ®Google Scholar
• Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991;14:67–79–80.
   PubMedGoogle Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3–B12.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Richmond P. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness. Expert Rev Vaccines. 2015;14:1277–1287.
   PubMed Web of Science ®Google Scholar
• Kaaijk P, Van Straaten I, Van De Waterbeemd B, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine. 2013;31:1065–1071.
   PubMed Web of Science ®Google Scholar
• Rots NY, Kleijne D Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. 16th International Pathogenic Neisseria Conference; 2008 Sept 7-12; Rotterdam, The Netherlands.
   Google Scholar
• Koeberling O, Ispasanie E, Hauser J, et al. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). Vaccine. 2014;32:2688–2695.
   PubMed Web of Science ®Google Scholar
• Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine. 2011;29:1413–1420.
   PubMed Web of Science ®Google Scholar
• Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000;287:1809–1815.
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816–1820.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103:10834–10839.
   PubMed Web of Science ®Google Scholar
• Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A. 2010;107:3770–3775.
   PubMed Web of Science ®Google Scholar
• Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789–799.
   PubMed Web of Science ®Google Scholar
• Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.  Mol Microbiol. 2005;55:687–698.
   Google Scholar
• Adu-Bobie J, Capecchi B, Serruto D, et al. Two years into reverse vaccinology. Vaccine. 2003;21:605–610.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Zagursky RJ, Lin SL, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77:234–252.
   PubMed Web of Science ®Google Scholar
• Pillai S, Howell A, Alexander K, et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine. 2005;23:2206–2209.
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee K-L, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379–389.
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088–2100.
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, et al. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010;28:2122–2129.
   PubMed Web of Science ®Google Scholar
• Seib KL, Brunelli B, Brogioni B, et al. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun. 2011;79:970–981.
   PubMed Web of Science ®Google Scholar
• Neisseria factor H binding protein sequence typing [Internet]; [updated 2016 Jul 18; cited 2016 Jul 19]. Available from: http://pubmlst.org/neisseria/fHbp/
   Google Scholar
• Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29:4739–4744.
   PubMed Web of Science ®Google Scholar
• Boan P, Metasan N, Tempone S, et al. Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011. BMC Infect Dis. 2014;14:686.
   PubMed Web of Science ®Google Scholar
• De Filippis I, De Lemos APS, Hostetler JB, et al. Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil. PLoS One. 2012;7:e33016.
   PubMed Web of Science ®Google Scholar
• Hoiseth SK, Murphy E, Andrew L, et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J. 2013;32:1096–1101.
   PubMed Web of Science ®Google Scholar
• Mothibeli KM, Du Plessis M, Von Gottberg A, et al. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine. 2011;29:2187–2192.
   PubMed Web of Science ®Google Scholar
• Biagini M, Spinsanti M, De Angelis G, et al. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci USA. 2016;113:2714–2719.
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Tan L, Exley RM, et al. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol. 2011;18:1002–1014.
   PubMed Web of Science ®Google Scholar
• Chang H, Vuong J, Kretz C, et al. Molecular epidemiology of Neisseria meningitidis serogroup B vaccine antigens in the United States, 2009-2014. Abstract 122. 20th International Pathogenic Neisseria Conference; 2016 Sep 4–9; Manchester, UK.
   Google Scholar
• Ala’aldeen DAA, Flint M, Oldfield NJ, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine. 2010;28:7667–7675.
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol Baltim Md 1950. 2006;177:501–510.
   Google Scholar
• Schneider MC, Prosser BE, Caesar JJE, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458:890–893.
   PubMed Web of Science ®Google Scholar
• Welsch JA, Ram S, Koeberling O, et al. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis. 2008;197:1053–1061.
   PubMed Web of Science ®Google Scholar
• Giuntini S, Reason DC, Granoff DM. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun. 2011;79:3751–3759.
   PubMed Web of Science ®Google Scholar
• Jiang H-Q, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086–6093.
   PubMed Web of Science ®Google Scholar
• Brehony C, Wilson DJ, Maiden MCJ. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiol Read Engl. 2009;155:4155–4169.
   PubMed Web of Science ®Google Scholar
• Muzzi A, Mora M, Pizza M, et al. Conservation of meningococcal antigens in the genus Neisseria. Mbio. 2013;4:e00163–113.
   PubMed Web of Science ®Google Scholar
• Tsang RS, Law DK, Gad RR, et al. Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: with special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A). Can J Infect Dis Med Microbiol. 2015;26:299–304.
   PubMed Web of Science ®Google Scholar
• Law DKS, Lefebvre B, Gilca R, et al. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets. BMC Microbiol. 2015;15:143.
   PubMed Web of Science ®Google Scholar
• Abad R, Medina V, Stella M, et al. Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with Other European Countries. PLoS One. 2016;11:e0150721.
   PubMed Web of Science ®Google Scholar
• Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine. 2011;29:1968–1973.
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–B97.
   PubMed Web of Science ®Google Scholar
• Montanari P, Bozza G, Capecchi B, et al. Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion. Cell Microbiol. 2012;14:368–385.
   PubMed Web of Science ®Google Scholar
• Mazzon C, Baldani-Guerra B, Cecchini P, et al. IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol Baltim Md 1950. 2007;179:3904–3916.
   Google Scholar
• Franzoso S, Mazzon C, Sztukowska M, et al. Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA). J Leukoc Biol. 2008;83:1100–1110.
   PubMed Web of Science ®Google Scholar
• Nägele V, Heesemann J, Schielke S, et al. Neisseria meningitidis adhesin NadA targets beta1 integrins: functional similarity to Yersinia invasin. J Biol Chem. 2011;286:20536–20546.
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Caugant DA, et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun. 2004;72:4217–4223.
   PubMed Web of Science ®Google Scholar
• Bambini S, De Chiara M, Muzzi A, et al. Neisseria adhesin A variation and revised nomenclature scheme. Clin Vaccine Immunol CVI. 2014;21:966–971.
   PubMed Web of Science ®Google Scholar
• Fagnocchi L, Biolchi A, Ferlicca F, et al. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun. 2013;81:560–569.
   PubMed Web of Science ®Google Scholar
• Rossi R, Granoff DM, Beernink PT. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine. 2013;31:5451–5457.
   PubMed Web of Science ®Google Scholar
• Beernink PT, Shaughnessy J, Braga EM, et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol Baltim Md 1950. 2011;186:3606–3614.
   Google Scholar
• Granoff DM, Costa I, Konar M, et al. Binding of complement factor H (FH) decreases protective Anti-FH binding protein antibody responses of Infant Rhesus Macaques immunized with a meningococcal Serogroup B vaccine. J Infect Dis. 2015;212:784–792.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Giuntini S, Gowans FA, et al. Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding. JCI Insight. 2016;1:e88907.
   PubMed Web of Science ®Google Scholar
• Seib KL, Scarselli M, Comanducci M, et al. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Rev Vaccines. 2015 Jun;14(6):841–859.
   PubMed Web of Science ®Google Scholar
• Johnson S, Tan L, Van Der Veen S, et al. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog. 2012;8:e1002981.
   PubMed Web of Science ®Google Scholar
• Esposito V, Musi V, De Chiara C, et al. Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis. J Biol Chem. 2011;286:41767–41775.
   PubMed Web of Science ®Google Scholar
• Lappann M, Otto A, Brauer M, et al. Impact of moderate temperature changes on Neisseria meningitidis adhesive phenotypes and proteome. Infect Immun. 2016 Nov 18;84(12):3484–3495.
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127–1137.
   PubMed Web of Science ®Google Scholar
• Bexsero® (Meningococcal Group B Vaccine). Prescribing information [Internet]; [ cited 2016 Jul 19]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf
   Google Scholar
• Trumenba® (Meningococcal Group B Vaccine) [Internet]; [ cited 2016 Jul 19]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf. Bexsero® (Meningococcal Group B Vaccine). Prescribing information. 2015.
   Google Scholar
• Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093–5107.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327–1348.
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568–1573.
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780–786.
   PubMedGoogle Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521–539.
   PubMedGoogle Scholar
• Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28:5023–5030.
   PubMed Web of Science ®Google Scholar
• Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccines Immunother. 2015;11:5–13.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107:19490–19495.
   PubMed Web of Science ®Google Scholar
• Plikaytis BD, Stella M, Boccadifuoco G, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19:1609–1617.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416–425.
   PubMed Web of Science ®Google Scholar
• Tzanakaki G, Hong E, Kesanopoulos K, et al. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol. 2014;14:111.
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Halperin SA, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine. 2013;32:124–130.
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33:2629–2636.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31:4968–4974.
   PubMed Web of Science ®Google Scholar
• Abad R, Biolchi A, Moschioni M, et al. A large portion of meningococcal antigen typing system-negative meningococcal strains from Spain is killed by Sera from adolescents and infants immunized with 4cmenb. Clin Vaccine Immunol. 2015;22:357–360.
   PubMed Web of Science ®Google Scholar
• Budroni S, Kleinschmidt A, Boucher P, et al. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. Vaccine. 2016;34:2579–2584.
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71–e79.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Ismaili S, Ypma E, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7:646–653.
   PubMed Web of Science ®Google Scholar
• McQuaid F, Snape MD, John TM, et al. Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. Can Med Assoc J. 2015;187:E215–E223.
   Web of Science ®Google Scholar
• Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. Can Med Assoc J. 2013;185:E715–E724.
   PubMed Web of Science ®Google Scholar
• McQuaid F, Snape MD, John TM, et al. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J. 2014;33:760–766.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825–835.
   PubMed Web of Science ®Google Scholar
• Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccines Immunother. 2014;10:1993–2004.
   PubMed Web of Science ®Google Scholar
• Torres F, Safadi MAP, Martinez A, et al. Immunogenicity and safety of a 2 or 3 dose primary series of meningococcal serogroup b vaccine in infants, and a 2-dose catch-up series in children. Abstract presented at 34th meeting of the European Society for Pediatric Infectious Diseases; 2016 May 10–14; Brighton, UK.
   Google Scholar
• Safadi MAP, Weckx L, Moreira Junior E, et al. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial. Vaccine. 2017 Mar 18;1–8.  doi:10.1016/j.vaccine.2017.03.002
   Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18:483–486.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617–624.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccines Immunother. 2013;9:2304–2310.
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74:15–30.
   PubMed Web of Science ®Google Scholar
• Perrett KP, McVernon J, Richmond PC, et al. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33:5217–5224.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123–2131.
   PubMed Web of Science ®Google Scholar
• Esposito S, Prymula R, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccines Immunother. 2014;10:2005–2014.
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu L-M, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. Jama. 2012;307:573–582.
   PubMed Web of Science ®Google Scholar
• Snape MD, Voysey M, Finn A, et al. Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age. Pediatr Infect Dis J. 2016;35:e113–e123.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Prymula R, Merrall E, et al. Meningococcal serogroup B vaccine (4CMenB): booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine. 2015;33:3850–3858.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Bernatowska E, Shcherbina A, et al. The immunogenicity of a serogroup B meningococcal vaccine (4CMenB) in children with complement deficiency, asplenia or splenic dysfunction. Abstract 122. 20th International Pathogenic Neisseria Conference, 2016 Sep 4–9; Manchester, UK.
   Google Scholar
• Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine. 2015;33:2500–2510.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Ramsay M, Borrow R, et al. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101:91–95.
   PubMed Web of Science ®Google Scholar
• De Serres G, Gariepy M, Billard M, et al. Initial dose of a multicomponent serogroup B meningococcal vaccine in the saguenay– Lac-Saint-Jean Region, Québec, Canada: an Interim safety surveillance report, 2014.
   Google Scholar
• Oster P, O’Hallahan J, Aaberge I, et al. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 2007;25:3075–3079.
   PubMed Web of Science ®Google Scholar
• Births in England and Wales - Office for National Statistics. http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandwales/2015
   Google Scholar
• Public Health England. Vaccine cuts cases of meningitis and septicaemia in UK infants - Press releases - GOV.UK. [Internet]; [ cited 2016 Oct 10]. Available from: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandwales/2015
   Google Scholar
• Findlow J. Vaccines for the prevention of meningococcal capsular group B disease: what have we recently learned? Hum Vaccines Immunother. 2016;12:235–238.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798–804.
   PubMed Web of Science ®Google Scholar
• Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15:641–658.
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:597–607.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31:1569–1575.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lucksinger GH, Absalon J, et al. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. Vaccine. 2016;34:1465–1471.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Beeslaar J, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatr Infect Dis Soc. 2016;5:180–187.
   PubMed Web of Science ®Google Scholar
• Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35:548–554.
   PubMed Web of Science ®Google Scholar
• Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35:673–682.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Ward BJ, Beeslaar J et al. Phase 3 trial of immunogenicity of bivalent rLP2086, a meningococcal serogroup B vaccine, in young adults: bactericidal activity against a panel of antigenically diverse strains. Abstract 160 presented at 20th International Pathogenic Neisseria Conference; 2016 Sep 4–9; Manchester, UK.
   Google Scholar
• Vesikari T, Senders S, Absalon J et al. Phase 3 trial of immunogenicity of bivalent rLP2086, a meningococcal serogroup B vaccine, in adolescents: bactericidal activity against a panel of antigenically diverse strains. Abstract 166 presented at 20th International Pathogenic Neisseria Conference; 2016 Sep 4–9; Manchester, UK.
   Google Scholar
• Vesikari T, Østergaard L, Diez-Domingo J, et al. Meningococcal serogroup B Bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatr Infect Dis Soc. 2016;5:152–160.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Beeslaar J et al. Persistence of meningococcal serogroup B–specific responses following vaccination with bivalent rLP2086. Abstract presented at 20th International Pathogenic Neisseria Conference; 2016 Sep 4–9. Manchester, UK.
   Google Scholar
• Martinon-Torres F, Gimenez-Sanchez F, Bernaola-Iturbe E, et al. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine. 2014;32:5206–5211.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J. 2012;31:1061–1068.
   PubMed Web of Science ®Google Scholar
• Brendish NJ, Read RC. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine. Expert Rev Vaccines. 2015;14:493–503.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Wang X et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college — Rhode Island, 2015. Abstract 040 presented at 20th International Pathogenic Neisseria Conference; 2016 Sep 4–9; Manchester, UK.
   Google Scholar
• Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP). Summary Report February 24, 2016 Atlanta, Georgia [Internet]; [ cited 2016 Oct 14]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2016-02.pdf
   Google Scholar
• Ladhani SN, Campbell H, Parikh SR, et al. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme–New challenges for public health. J Infect. 2015;71:611–614.
   PubMed Web of Science ®Google Scholar
• Wise J. MenB vaccine programme cuts cases of meningitis and septicaemia in infants. Bmj. 2016;354:i4839.
   PubMed Web of Science ®Google Scholar
• Basta NE, Christensen H. 4CMenB vaccine effectiveness: reasons for optimism. Lancet. 2016 Dec 3;388(10061):2719–2721.
   Google Scholar
• Parikh SR, Andrews N, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016 Dec 3;388(10061):2775–2782.
   Google Scholar
• Watson PS, Turner DPJ. Clinical experience with the meningococcal B vaccine, Bexsero(®): prospects for reducing the burden of meningococcal serogroup B disease. Vaccine. 2016;34:875–880.
   PubMed Web of Science ®Google Scholar
• Biswas HH, Han GS, Wendorf K, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a university - California, 2016. Morb Mortal Wkly Rep. 2016;65:520–521.
   PubMed Web of Science ®Google Scholar
• Basta NE, Mahmoud AAF, Wolfson J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375(3):220–228.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375:1594–1595.
   PubMed Web of Science ®Google Scholar
• MenB and rotavirus vaccines - Ireland’s Health Service [Internet]; [ cited 2016 Aug 18]. Available from: http://www.hse.ie/eng/health/immunisation/news/menbrotavacc.html
   Google Scholar
• Signorelli C, Chiesa V, Odone A. Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives. J Prev Med Hyg. 2015;56:E125–E132.
   PubMedGoogle Scholar
• Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on immunization practices, 2015. Morb Mortal Wkly Rep. 2015;64:608–612.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. Morb Mortal Wkly Rep. 2015;64:1171–1176.
   PubMed Web of Science ®Google Scholar
• Hong E, Giuliani MM, Deghmane A-E, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2013;31:1113–1116.
   PubMed Web of Science ®Google Scholar
• Abad R, López EL, Debbag R, et al. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142:2461–2470.
   PubMed Web of Science ®Google Scholar
• Tomei S, Biolchi A, Brunelli B, et al. Potential coverage of the BEXSERO® MenB vaccine on non-B meningococci. Abstract P30. 19th International Pathogenic Neisseria Conference (IPNC); 2014 Oct 12–17; Asheville, NC.
   Google Scholar
• Ladhani SN, Giuliani MM, Biolchi A, et al. Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis. 2016;22:309–311.
   PubMed Web of Science ®Google Scholar
• Petoussis-Harris H, Paynter J, Morgan J, et al. Effectivness of a group B OMV meningococcal vaccine on gonorrhea in New Zealand - a case control study. Abstract 20th International Pathogenic Neisseria Conference; 2016 Sep 4–9; Manchester, UK.
   Google Scholar
• Domnich A, Gasparini R, Amicizia D, et al. Meningococcal antigen typing system development and application to the evaluation of effectiveness of meningococcal B vaccine and possible use for other purposes. J Immunol Res. 2015;2015:1–9.
   Web of Science ®Google Scholar